Relay Therapeutics is trading 10.72% down now at $17.27, with the decline appearing primarily linked to broader risk-off trading; no clear company-specific announcement emerged on September 23, 2026.
- U.S. indexes fell as oil and Treasury yields rose, despite biotech outperforming.
- Relay Therapeutics’ investor-relations page lists no new September 23 release; available coverage says the catalyst is unclear.
- The decline reverses part of September 22’s 6.38% gain.